Showing 5541-5550 of 6038 results for "".
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Syneron Introduces PicoWay Resolvehttps://practicaldermatology.com/news/syneron-introduces-picoway-resolve/2458850/Syneron Medical Ltd. introduced the PicoWay Resolve™, a dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve frac
- ZELTIQ Receives FDA Clearance to Treat Submental Fat With Coolsculpting Procedurehttps://practicaldermatology.com/news/zeltiq-receives-fda-clearance-to-treat-submental-fat-with-coolsculpting-procedure/2458855/The FDA granted an expanded clearance for ZELTIQ(R) Aesthetics, Inc.’s Coolsculpting procedure, paving the way for the introduction of the new, CoolMini(TM) applicator, which is designed to treat smaller pockets of fat, including the submental, or chin fat area. The CoolSculpting(R) procedu
- Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/secukinumab-phase-iii-data-confirm-significant-efficacy-in-patients-with-psoriatic-arthritis/2458858/Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a Phase III
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Dermira: Kathleen Sebelius Elected to Board of Directorshttps://practicaldermatology.com/news/dermira-kathleen-sebelius-elected-to-board-of-directors/2458861/Dermira, Inc. has elected Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors,&quo
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and